APOTHEEK LOPPEM
ActiveSummary
APOTHEEK LOPPEM has been active since 1983 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €426,678 and a net result of -€8,213. Equity has been growing by about 4% per year since 2018. Its solvency ranks better than 79% of 5,039 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
Source: KBO- Status
- Active since 22-12-1983 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2025
- Establishment unit
- 2.037.767.684 8210 Zedelgem, since 07-03-2002
- Financial year end
- 31 December
- Peppol
- Reachable since 13-02-2024
Board and ownership
- Ann HofmannManaging director
- ANN HOFMANN100%30-06-2025 annual accounts of ANN HOFMANN
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
- Gross margin
- €136,816
- ▲ 22.9%
- Turnover
- ≈ €640,000
- estimated
- Loss
- €8,213
- ▼ 51.7%
- Equity
- €426,678
- ▼ 1.9%
- Total assets
- €648,217
- ▲ 1.9%
- Employees on 31-12-2025
- 2
- =
Score breakdownraises riskSector: Retail trade (NACE 47)lowers riskFounded in 1983Equity €426,678 (65.8% of total assets)Size: 1.5 FTE, total assets €648,217Show the evidence
Checked score
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 78% of them on solvency, 48% on liquidity, 26% on profitability and 35% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 6 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
- Caution: 2 loss-making years in a rowloss in financial year 2025 -€8,213 View
Recent changes
- · Gazette deed Company renamed from SURMONT to APOTHEEK LOPPEMChange of role: ANN HOFMANN, from director to managing director · Reappointment: ANN HOFMANN (director) · Permanent representative: Ann Hofmann
- · Gazette deed Resignations: Helena De Meurechy (director and managing director) and Magali Surmont (director)Appointment: BV Ann Hofmann (director and managing director) · Permanent representative: Ann Hofmann
Comparable companies
These companies have the same main activity as APOTHEEK LOPPEM: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €547,000 and €622,000, founded between 1975 and 1991.
| Company | Total assets | Gross margin |
|---|---|---|
| APOTHEEK LOPPEM Zedelgem | €648,217 | €136,816 |
| APOTHEEK CHARLOTTE SULMON Zwevegem | €621,627 | €160,255 |
| VERSTRAETE JEROEN APOTHEEK Harelbeke | €560,565 | €163,995 |
| Apotheek Verfaillie Tielt | €546,947 | €147,126 |
| PHARMAHEALTH Zottegem | €607,296 | €135,678 |
| Apotheek Ravestijn Brasschaat | €594,034 | €126,901 |
| PHARMACIE BRENARD Rebecq | €615,443 | €151,981 |
Key facts about APOTHEEK LOPPEM
- What is the company number of APOTHEEK LOPPEM?
- The company number of APOTHEEK LOPPEM is 0425.373.902. The VAT number is the same number with BE in front: BE 0425.373.902.
- Where is APOTHEEK LOPPEM based?
- The registered office is at Rijselsestraat 29, 8210 Zedelgem.Company details
- What does APOTHEEK LOPPEM do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK LOPPEM?
- The legal form of APOTHEEK LOPPEM is Public limited company (NV).
- When was APOTHEEK LOPPEM founded?
- APOTHEEK LOPPEM was founded on 22-12-1983.
- Is APOTHEEK LOPPEM still active?
- Yes, APOTHEEK LOPPEM is an active enterprise in the KBO register.
- How many employees does APOTHEEK LOPPEM have?
- APOTHEEK LOPPEM had an average of 1.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does APOTHEEK LOPPEM fall under?
- In its 2025 annual accounts, APOTHEEK LOPPEM states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of APOTHEEK LOPPEM?
- The turnover in financial year 2025 is ≈ €640,000. This figure is estimated from the gross margin of €136,816 and 51 comparable companies (NACE 477). It probably lies between €430,000 and €1.2m.
- Is APOTHEEK LOPPEM profitable?
- In financial year 2025, APOTHEEK LOPPEM made a loss of €8,213.
- Where can I find the annual accounts of APOTHEEK LOPPEM?
- APOTHEEK LOPPEM filed 42 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of APOTHEEK LOPPEM due?
- APOTHEEK LOPPEM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.